Literature DB >> 11350486

Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts.

M De Waele1, W Renmans, K Vander Gucht, K Jochmans, R Schots, J Otten, F Trullemans, P Lacor, I Van Riet.   

Abstract

Leukaemic cells show a low clonogenic activity and a heterogeneous proliferative response to growth factors. We investigated whether this could be due to an altered expression of growth factor receptors on the leukaemic precursors. Receptors for G-CSF, stem cell factor (SCF), IL-3, IL-6 and IL-7 were detected on CD34+ cells in AML and B-lineage ALL with monoclonal antibodies and flow cytometry. The expression was compared with that on myeloid and B-lymphoid CD34+ cells in normal bone marrow. Leukaemic CD34+ cells expressed the same receptors as their normal counterparts. AML and B-lineage ALL could be distinguished by the growth factor receptor profile of their CD34+ cells. SCFR, G-CSFR and IL-6Ralpha were found in AML, IL-7R in B-lineage ALL and IL-3Ralpha in both. IL-3Ralpha was upregulated in AML and B-lineage ALL CD34+ cells, while samples with low or high expression were present for the other receptors. This variable expression could correlate with the heterogeneous response of leukaemic cells to growth factors. Functional studies on isolated CD34+ cells are needed to investigate this further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350486     DOI: 10.1034/j.1600-0609.2001.00320.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.

Authors:  A Pardanani; K K Reichard; D Zblewski; R A Abdelrahman; E A Wassie; W G Morice Ii; C Brooks; K L Grogg; C A Hanson; A Tefferi; D Chen
Journal:  Leukemia       Date:  2015-12-18       Impact factor: 11.528

2.  Overcoming adaptive therapy resistance in AML by targeting immune response pathways.

Authors:  Katelyn Melgar; Morgan M Walker; LaQuita M Jones; Lyndsey C Bolanos; Kathleen Hueneman; Mark Wunderlich; Jian-Kang Jiang; Kelli M Wilson; Xiaohu Zhang; Patrick Sutter; Amy Wang; Xin Xu; Kwangmin Choi; Gregory Tawa; Donald Lorimer; Jan Abendroth; Eric O'Brien; Scott B Hoyt; Ellin Berman; Christopher A Famulare; James C Mulloy; Ross L Levine; John P Perentesis; Craig J Thomas; Daniel T Starczynowski
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

3.  miR-155 is associated with the leukemogenic potential of the class IV granulocyte colony-stimulating factor receptor in CD34⁺ progenitor cells.

Authors:  HaiJiao Zhang; Lilia Goudeva; Stephan Immenschuh; Axel Schambach; Julia Skokowa; Britta Eiz-Vesper; Rainer Blasczyk; Constança Figueiredo
Journal:  Mol Med       Date:  2015-04-09       Impact factor: 6.354

4.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.

Authors:  S J Busfield; M Biondo; M Wong; H S Ramshaw; E M Lee; S Ghosh; H Braley; C Panousis; A W Roberts; S Z He; D Thomas; L Fabri; G Vairo; R B Lock; A F Lopez; A D Nash
Journal:  Leukemia       Date:  2014-04-07       Impact factor: 11.528

5.  High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.

Authors:  Rieneke van de Ven; Sue Ellen Verbrugge; Anneke W Reurs; Hetty J Bontkes; Erik Hooijberg; Gerrit Jansen; Rik J Scheper; George L Scheffer; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2011-03-24       Impact factor: 6.968

6.  Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.

Authors:  Werner Van Belle; Nina Anensen; Ingvild Haaland; Øystein Bruserud; Kjell-Arild Høgda; Bjørn Tore Gjertsen
Journal:  BMC Bioinformatics       Date:  2006-04-10       Impact factor: 3.169

7.  Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.

Authors:  Hélène Bonnevaux; Stephane Guerif; Jana Albrecht; Erwan Jouannot; Thibaud De Gallier; Christian Beil; Christian Lange; Wulf Dirk Leuschner; Marion Schneider; Cendrine Lemoine; Anne Caron; Céline Amara; Cédric Barrière; Justine Siavellis; Valérie Bardet; Ernesto Luna; Pankaj Agrawal; Donald R Drake; Ercole Rao; Peter Wonerow; Chantal Carrez; Véronique Blanc; Karl Hsu; Dmitri Wiederschain; Paula G Fraenkel; Angéla Virone-Oddos
Journal:  Oncoimmunology       Date:  2021-08-31       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.